enzastaurin has been researched along with Carcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amant, F; Bauknecht, T; Darstein, C; Kania, M; Michel, AL; Musib, L; Oskay-Oezcelik, G; Sehouli, J; Vergote, I | 1 |
| Albert, S; Astorgues-Xerri, L; Benhadji, KA; Bieche, I; Emami, S; Faivre, S; Gespach, C; Hammel, P; Raymond, E; Serova, M; Theou-Anton, N; Vidaud, D; Vidaud, M | 1 |
1 trial(s) available for enzastaurin and Carcinoma
| Article | Year |
|---|---|
Carboplatin and paclitaxel in combination with oral enzastaurin in advanced ovarian or primary peritoneal cancer: results from a safety lead-in study.
Topics: Administration, Oral; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Disease Progression; Drug Interactions; Female; Humans; Indoles; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2009 |
1 other study(ies) available for enzastaurin and Carcinoma
| Article | Year |
|---|---|
Epithelial-to-mesenchymal transition and oncogenic Ras expression in resistance to the protein kinase Cbeta inhibitor enzastaurin in colon cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Dedifferentiation; Colonic Neoplasms; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Epithelial Cells; Gene Expression Regulation, Neoplastic; Genes, ras; HCT116 Cells; HT29 Cells; Humans; Indoles; Mesenchymal Stem Cells; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors; Tumor Cells, Cultured | 2010 |